CARSGEN-B(02171): First patient infusion completed for CT0596 in China Phase I registrational clinical trial

CARSGEN-B(02171) announced that CT0596, a BCMA-targeted universal CAR-T cell product, has completed first patient infusion in its Phase I registrational clinical trial in China for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM). The IIT study results of CT0596 were presented as a poster at the 2026 European Hematology Association (EHA) Annual Congress. CT0596 is a BCMA-targeted universal CAR-T cell therapy developed based on CARsgen's independently developed THANK-u Plus platform, and is currently undergoing a Phase I registrational clinical trial in R/R MM. Preliminary IIT results showed that CT0596 demonstrated preliminary favorable safety and encouraging efficacy signals in R/R MM and primary plasma cell leukemia. The Company also plans to further explore its application in other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells.